Analysis of Hospitalization and Readmissions after CAR T Cell Therapy

Conclusions: CAR T-cell therapy is a promising evolving therapy for the treatment of relapsed, refractory hematologic malignancies. Further evaluation of pooled data may allow for early identification of patterns of deterioration which may limit premature hospital discharge, early readmission, and therapy-associated mortality.Figure 1.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: O'Donnell, E., Deng, H., Safavi, K., Driscoll, W., Nikolov, M., Yee, A. J., Raje, N., Frigault, M., Handiziar, D. Tags: 904. Outcomes Research-Malignant Conditions: Poster I Source Type: research